The estimated Net Worth of Sam L Barker is at least 255 千$ dollars as of 28 April 2024. Samuel Barker owns over 8,032 units of Lexicon Pharmaceuticals Inc stock worth over 148,127$ and over the last 18 years he sold LXRX stock worth over 43$. In addition, he makes 107,179$ as Independent Director at Lexicon Pharmaceuticals Inc.
Samuel has made over 13 trades of the Lexicon Pharmaceuticals Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 8,032 units of LXRX stock worth 13,574$ on 28 April 2024.
The largest trade he's ever made was buying 40,000 units of Lexicon Pharmaceuticals Inc stock on 18 April 2008 worth over 78,400$. On average, Samuel trades about 3,502 units every 130 days since 2007. As of 28 April 2024 he still owns at least 87,649 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Samuel Barker stock trades at the bottom of the page.
Dr. Samuel L. Barker Ph.D. serves as Independent Director of the Company. Dr. Barker has been a director since March 2000 and served as chairman of our board of directors from 2005 to 2012. Dr. Barker previously co-founded and served as president and chief executive officer of Clearview Projects, Inc., a provider of partnering and transaction services to biopharmaceutical companies. Dr. Barker served in a series of leadership positions at Bristol-Myers Squibb Company until his retirement in 1999. His positions at Bristol-Myers Squibb included service as executive vice president, Worldwide Franchise Management and Strategy; president, United States Pharmaceuticals; and president, Bristol-Myers Squibb Intercontinental Commercial Operations. Dr. Barker also previously held executive positions in research and development, manufacturing, finance, business development and sales and marketing at Squibb Pharmaceuticals. Dr. Barker currently serves as a director of Cyclacel Pharmaceuticals, Inc. Dr. Barker received his B.S. from Henderson State College, his M.S. from the University of Arkansas and his Ph.D. from Purdue University.
As the Independent Director of Lexicon Pharmaceuticals Inc, the total compensation of Samuel Barker at Lexicon Pharmaceuticals Inc is 107,179$. There are 11 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of 3,870,290$.
Samuel Barker is 77, he's been the Independent Director of Lexicon Pharmaceuticals Inc since 2012. There are 1 older and 17 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.
Sam's mailing address filed with the SEC is 2445 TECHNOLOGY FOREST BLVD., 11TH FLOOR, THE WOODLANDS, TX, 77381.
Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over 161,951$ worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth 731,672,961$ . The most active insiders traders include International S.C.A.Minne P...、International S.C.A.Wittouc...、Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of 5,348,701$. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth 97,252,909$.
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: